MX363662B - Métodos para incrementar la sensibilidad a insulina mediante agonistas de receptores serotonérgicos 5-ht2. - Google Patents
Métodos para incrementar la sensibilidad a insulina mediante agonistas de receptores serotonérgicos 5-ht2.Info
- Publication number
- MX363662B MX363662B MX2012011700A MX2012011700A MX363662B MX 363662 B MX363662 B MX 363662B MX 2012011700 A MX2012011700 A MX 2012011700A MX 2012011700 A MX2012011700 A MX 2012011700A MX 363662 B MX363662 B MX 363662B
- Authority
- MX
- Mexico
- Prior art keywords
- insulin
- sensitivity
- increasing
- receptor antagonists
- receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a la participación de receptores serotonérgicos 5-TH2 con el incremento en la sensibilidad a la insulina, principalmente por aumentar la captura periférica de glucosa. La presente invención tiene como objetivo principal la utilización de agonistas de receptores serotonérgicos 5-HT2, como por ejemplo indorrenato (agente hipertensivo que actúa como agonista de receptores 5-HT1A centrales) en composiciones farmacéuticas para mejorar la sensibilidad a la insulina, al actuar como agonista 5-HT2 en la periferia.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2012011700A MX363662B (es) | 2012-10-08 | 2012-10-08 | Métodos para incrementar la sensibilidad a insulina mediante agonistas de receptores serotonérgicos 5-ht2. |
PCT/IB2013/059161 WO2014057408A1 (en) | 2012-10-08 | 2013-10-07 | Methods for increasing insulin sensitivity by agonists of serotonergic receptors 5-ht2 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2012011700A MX363662B (es) | 2012-10-08 | 2012-10-08 | Métodos para incrementar la sensibilidad a insulina mediante agonistas de receptores serotonérgicos 5-ht2. |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2012011700A MX2012011700A (es) | 2014-04-25 |
MX363662B true MX363662B (es) | 2019-03-27 |
Family
ID=49917193
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012011700A MX363662B (es) | 2012-10-08 | 2012-10-08 | Métodos para incrementar la sensibilidad a insulina mediante agonistas de receptores serotonérgicos 5-ht2. |
Country Status (2)
Country | Link |
---|---|
MX (1) | MX363662B (es) |
WO (1) | WO2014057408A1 (es) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9902047D0 (en) * | 1999-01-29 | 1999-03-17 | Cerebrus Ltd | Chemical compounds XI |
US20080103179A1 (en) | 2006-10-27 | 2008-05-01 | Tam Peter Y | Combination Therapy |
US7019010B2 (en) | 2001-09-27 | 2006-03-28 | Novertis Ag | Combinations |
WO2006132196A1 (ja) | 2005-06-08 | 2006-12-14 | Asahi Kasei Pharma Corporation | β3作動薬を含有する新規な医薬 |
WO2008122019A1 (en) | 2007-04-02 | 2008-10-09 | Cypress Biosciences, Inc. | Improving the tolerability of both mirtazapine and reboxetine by using them in combination |
-
2012
- 2012-10-08 MX MX2012011700A patent/MX363662B/es unknown
-
2013
- 2013-10-07 WO PCT/IB2013/059161 patent/WO2014057408A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2014057408A1 (en) | 2014-04-17 |
MX2012011700A (es) | 2014-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20150296A (es) | Novedosos derivados de bencimidazol como antagonistas de ep4 | |
PH12015501247A1 (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
SG195375A1 (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
UA111640C2 (uk) | ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2 | |
EA201501122A8 (ru) | Новые агонисты соматостатиновых рецепторов подтипа 4 (sstr4) | |
MY160665A (en) | Spiropiperidine compounds as orl-1 receptor antagonists | |
GB0906579D0 (en) | Pharmaceuticals, compositions and methods of making and using the same | |
MX2012012897A (es) | Nuevos derivados de ciclohexilamina que tienen actividad como agonistas adrenergicos beta-2 y como antagonistas muscarinicos m3. | |
MX2014004387A (es) | Nuevos derivados de ciclohexilamina que tienen actividad como agonistas adrenergicos b2 y como antagonistas muscarinicos m3. | |
BR112015012746A2 (pt) | compostos que possuem atividade de antagonista de receptores muscarínicos e agonista de receptores beta2-adrenérgicos | |
EA201290355A1 (ru) | Спиропиперидиновые соединения в качестве антагонистов рецептора orl-1 | |
EA201390977A1 (ru) | Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона | |
PH12017501424B1 (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
MX2014002473A (es) | Compuestos (tieno [2,3-b] [1,5] benzoxazepin -4 -il) piperazin- 1 - ilo como angonistas inversos h1 / antagonistas 5 -ht2a de actividad doble. | |
BR112013002846A2 (pt) | derivados de tandospirona deuterada como agonista do receptor de 5-ht1a | |
MX2014007042A (es) | Composiciones de la buprenorfina y antagonistas de los receptores opioide-mu. | |
CR20140257A (es) | Nuevos 2h-indazoles como antagonistas del receptor ep2 | |
EP2968293A4 (en) | PAIN RELIEF COMPOSITIONS COMPRISING AN OPIOID / TOLL LIKE RECEPTOR 4 ANTAGONIST, DEXTROENANTIOMERS, AND METHOD OF USE THEREOF | |
MX341132B (es) | Compuesto (tieno [2-3-b] [1,5] benzoxazepin-4-il) piperazin-1-ilo como agonista h1 inversos/antagonistas 5-ht2a de actividad doble. | |
MX2012011700A (es) | Metodo para incrementar la sencibilidad a insulina mediante agonista de receptores serotonergicos 5-ht2. | |
TN2013000429A1 (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
MX365594B (es) | Compuestos de (tieno [2,3-b] [1,5] benzoxazepin-4-il) piperazin-1-ilo de actividad doble como agonista inversos de h1/antagonistas de 5-ht2a. | |
UA96048C2 (ru) | Применение антагониста рецепторов интерлейкина-1 как средства фригопротекторного действия | |
UA96037C2 (ru) | Применение антагониста рецепторов интерлейкина-1 как средства антиалкогольного действия | |
UA109581C2 (uk) | Сполуки з активністю антагоністів мускаринових рецепторів і агоністів адренергічного рецептора бета2 |